semaj83/ctmatch_classification huggingface dataset:
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Survival After IPA Risk Factors for IPA > 18 years positive aspergillus culture in respiratory tract sample OR positive aspergillus galactomannan in respiratory tract sample  no inform consent age < 18 years
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Immunocompromised Patient Aspergillosis Fusarium Any adult ≥18 years old Patients where a new course of voriconazole is indicated for suspected or confirmed invasive aspergillosis or other serious fungal infections that is deemed by the treating physician to be susceptible to voriconazole Patients must have venous access to permit the administration of voriconazole and enable the procurement of multiple plasma samples to measure voriconazole concentrations Estimated creatinine clearance ≥ 50 mL/min Able to give written informed consent Considered fit to receive the trial treatment Able to remain in the hospital for at least 5 days or until they complete their trial treatment Female patients must satisfy the investigator that they are not pregnant, or are not of childbearing potential, or are using adequate contraception Men must also use adequate contraception  Patients with an estimated creatinine clearance < 50 mL/minute (this precludes the use of intravenous voriconazole) Patients receiving any form of renal replacement therapy i.e. haemodialysis or haemofiltration Patients with hepatic insufficiency Female patients that are pregnant, breast feeding or planning pregnancy during the study Past history of intolerance to voriconazole Age <18 Evidence of a clinically relevant fungal isolate that is resistant to voriconazole QT prolongation on ECG Use of other medications that contraindicate the use of voriconazole Patients receiving any other medications that are contraindicated with the use of voriconazole i.e. terfenadine, long acting barbiturates, ergot alkaloids, etc. (Refer to SMPC). Only patients on rifampicin, rifabutin, phenytoin, and carbamazepine would have voriconazole precluded. Voriconazole influences with the pharmacokinetics of many additional agents
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lung Transplant Infection Lower Respiratory Tract Infection. Post bilateral sequential lung transplant Capable of performing airway clearance techniques / nebulisers Pulmonary exacerbation as defined by Fuchs et al Must be productive of sputum Able to provide informed consent within 48 hours of presentation *Fuchs Scale(8): Treatment with / without parenteral antibiotics for 4/12 signs and symptoms Change in sputum New or increased haemoptysis Increased cough Increased dyspnoea  Paediatric transplant <18yrs Single lung transplant native lung physiology may confound outcome measures Interstate unable to complete follow up Unable to perform lung function testing Unable to complete subjective outcome measures unable to read English fluently Critically unwell / ICU / ventilator dependent Within 2 months of transplant date *Cystic Fibrosis will be stratified
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Healthy Aged from 18 to 40 years old, age difference is not more than 10 years old within the same batch of healthy volunteers, the male to female ratio of cases is 1:1. Body mass index should be in the range of 20 to 27 Body Mass Index BMI: weight (Kg)/ height (M2) Agreed to participate in the test and sign the informed consent Subjects should comply with the requirements of the clinical trial protocol and be followed Subjects have no history of TB (Tuberculosis)or family history of tuberculosis People have no pulmonary tuberculosis or extrapulmonary tuberculosis,respiratory symptom or systemic symptoms People have no tuberculosis focus after examination by X-ray chest radiograph and sputum bacilli Subjects have no acute or chronic disease, acute infectious diseases, dermatoses or skin allergy caused by various reasons Physical condition: have no history of heart, liver, kidney, gastrointestinal tract, nervous system, or metabolic disturbance, etc. ECG, blood pressure, heart rate, respiratory status and lab test indexes including blood, urine, liver and kidney function, etc are all normal within 4 weeks before screening No close contacts of tuberculosis Subjects have not participated in other clinical drug trials or inoculated against other prophylactic and immune globulin in the nearly 3 months  Health people have close contacts of TB (Tuberculosis)patients, especially excreter in 3 weeks before selection Suffering from any other serious disease, e.g. during cancer treatment, autoimmune disease, progressive atherosclerosis, diabetes accompanied with complications, chronic obstructive pulmonary disease (COPD) needing oxygen therapy, acute or progressive liver or kidney disease, congestive heart failure, etc People have history of allergy, convulsions, epilepsy, cerebropathy, neurological symptoms and signs Patients who have impaired or abnormal immune function, e.g. patients treated with immunosuppressor or immunopotentiator, received immunoglobulin preparation or blood products or plasma extraction outside the gastrointestinal tract in 3 months, human immunodeficiency virus or related diseases Acute febrile illness and infection Taking part in other clinic trials Subjects have participated in any other clinical drug trials in 3 months before our clinical tests Allergic constitution, e.g. patients have allergic history to two or more kinds of drugs or food, or drug components Substance abuse and alcoholics  Pregnant or breast feeding women
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Dental Caries Two approximal carious lesions on different teeth with at least one tooth in between Both study lesions must not require an invasive treatment Size and form of the lesions: the lesions must be fully visible and assessable on radiographs The two carious lesions must fall into classes D2 (inner half of enamel) D3 (outer part of dentine) but only if very little dentine is involved (enamel-dentine junction) Able and willing to observe good oral hygiene throughout the study Age ≥ 18 years and ≤ 65 years Willing and able to attend the on-study visits Willing and able to understand all study-related procedures  The two study test lesions are located on adjacent teeth Fluoride varnish application < 3 months prior to study treatment Tooth with numerous carious lesions Evidence of tooth erosion History of head and neck illnesses (e.g. head/neck cancer) Any pathology or concomitant medication affecting salivary flow or dry mouth Any metabolic disorders affecting bone turnover Patient suffers from diabetes Concurrent participation in another clinical trial Women who are breast-feeding, pregnant or who plan a pregnancy during the study
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Dental Caries Two approximal carious lesions on different teeth with at least one tooth in between Both study lesions must not require an invasive treatment Size and form of the lesions: the lesions must be fully visible and assessable on radiographs The two carious lesions must fall into classes D1 (outer half of enamel) D2 (inner half of enamel) D3 (outer part of dentine) but only if very little dentine is involved (enamel-dentine junction) Able and willing to observe good oral hygiene throughout the study Age ≥ 18 years and ≤ 65 years Willing and able to attend the on-study visits Willing and able to understand all study-related procedures Written informed consent before participation in the study  The two study test lesions are located on adjacent teeth Fluoride varnish application < 3 months prior to study treatment Tooth with numerous carious lesions Evidence of tooth erosion History of head and neck illnesses (e.g. head/neck cancer) Any pathology or concomitant medication affecting salivary flow or dry mouth Any metabolic disorders affecting bone turnover Patient suffers from diabetes Concurrent participation in another clinical trial Women who are breast-feeding, pregnant or who plan a pregnancy during the study
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 30.0-60.0,  Type 2 Diabetes Mellitus Pulmonary Tuberculosis Age 30 to 60 years Patients having both TB and type 2 DM Patients consenting to participate No history of previous ATT Plane to have ATT and DM treatment  Age less than 30 years or greater than 60 years Pregnant women Patients having either TB or type 2 DM Patients refuse to participate Patients having extra-pulmonary TB or Multi-drug resistant MDR TB or relapse cases Patients having hepatic or renal diseases or HIV infection Patients having hypo or hyper-parathyroidism Patients on corticosteroids or immunosuppressive or thiazides diuretics or any other drugs known to interfere with vitamin D levels
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Influenza with confirmed influenza A(H1N1,H3N2) or influenza B virus infection by real time RT-PCR (rRT-PCR), age between 18-65 years old, axillary temperature ≥38ºC and with at least two constitutional symptoms (headache, chill, myalgia ，or fatigue) and one respiratory symptom (cough ，sore throat,or coryza) . Illness onset had to be within 36 hours, and informed consent was obtained  age younger than 18 or older than 65 years old patients confirmed with bronchitis, pneumonia,pleural effusion and interstitial lung disease by Chest imaging (chest X-ray or CT)  Blood routine screening tests shows numeration of leukocyte 10.0×109/L or Neutrophil percentage ≥80% Those have got suppurative tonsillitis or cough purulent sputum Those with underling primary disorders, such as hematological disease, chronic obstructive pulmonary disease（FEV1/FVC＜70％，FEV1/ predicated value＜50％； or respiratory failure or right heart failure）， hepatic disease（ALT or AST≥triple ULN）, renal disease（Serum Creatinine＞2mg/dL）,chronic congestive heart failure( NYHA Ⅲ-IV) Patient is allergic to the study medication(s). 8. Women who are pregnant or may possibly become pregnant or are lactating with a positive urine pregnant test, obesity (abody mass index (BMI) of 25 kg/m2 or more) Those with immunodeficiency ,such as malignant tumor ; Organs or bone marrow transplantation ; AIDS ;or taking immune inhibitors during the last 3 months Doubt or does alcohol/drug abuse of history. 11. Those have participated in other clinical trial within three month before study randomization Two weeks before the test , those with acute respiratory Infection，otitis,or nasosinusitis  Those already vaccinated or who will receive influenza vaccine. 14.other reasons not suitable for enrollment based on the investigator's discretion
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 30.0-85.0,  Invasive Pulmonary Aspergillosis COPD Cases of invasive pulmonary aspergillosis secondary to COPD  Use of voriconazole or itraconazole or amphotericin B or caspofungin or micafungin within 4 weeks prior to enrollment Known allergy to voriconazole Severe impairment of live or kidney function Septic shock Unwilling to sign informed consent
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cholecystitis Signed informed consent All patients deemed to have a clinical and surgical indication to undergo a LESS cholecystectomy  Pregnancy Breastfeeding BMI>35 Serious comorbidities precluding a LESS cholecystectomy Known or suspected neuromuscular disorders impairing neuromuscular function Allergies to muscle relaxants, anesthetics or narcotics utilized for this study A (family) history of malignant hyperthermia A contraindication for neostigmine administration Chronic opioid use Prolonged QT syndrome
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 40.0-75.0,  COPD(Chronic Obstructive Pulmonary Disease) Clinical diagnosis of COPD according to GOLD 2013  A history of asthma or other chronic lung diseases Take Antioxidant therapy There are new or recurrent symptomatic myocardial ischemia, severe arrhythmia, cardiac insufficiency cerebrovascular disease Senile dementia or cognitive impairment cancer Severe liver and kidney and other viscera function insufficiency Language communication barriers Limb activity disorder The last 3 months participated in sports training
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Obstructive Pulmonary Disease Established diagnosis of COPD by medical doctor (based on clinical history or pulmonary function test) Smoking history of at least 10 pack-years CT Thorax available for assessment of bronchiectasis FEV1 >= 30%  Mechanical or non-invasive ventilation Other main respiratory diagnosis other than COPD Active mycobacterial disease Immunosuppression other than steroids Active cancer treatment
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Tuberculosis Age 18 to 65 years with body weight from 30 kg to 90 kg Sputum acid-fast bacilli (AFB) smear positive (at least 1+ on the WHO International Union Against Tuberculosis and Lung Disease scale) Likely able to produce approximately 10 mL of sputum per day Xpert MTB/RIF-confirmed M.tb Rifampin-sensitive pulmonary tuberculosis as indicated by Xpert MTB/RIF Isoniazid urine screen negative ALT < 3X upper limit of normal, creatinine < 2X upper limit of normal Willingness to have samples stored  Clinically suspected disseminated TB or acuity of illness too much as deemed by clinicians Has been treated for tuberculosis within the past 3 years Treatment with agents known to have anti-tuberculosis activity (e.g., fluoroquinolones, linezolid) for any indications during the current episode of clinical illness or within 2 months prior to screening, whichever is longer Cirrhosis or chronic kidney disease Disease complications or concomitant illness that might compromise safety or the interpretation of trial endpoints, such as known diagnosis of chronic inflammatory condition (e.g., sarcoidosis, rheumatoid arthritis, and connective tissue disorder) Use of immunosuppressive medications, such as TNF-alpha inhibitors or systemic or inhaled corticosteroids, within 2 weeks prior to screening Subjects with diabetes, point of care HbA1c above 6.5, or random glucose over 200 mg/dL Conditions which compromise the subject s ability to take or absorb oral drugs Normal PA-Chest radiograph, determined during screening Total lung (left or right) collapse on PA-Chest radiograph
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Tuberculosis At least 18 years of age Diagnosis of TB (and/or NTM for NIH clinical center subjects) Ongoing signs and/or symptoms of pulmonary TB (and/or NTM at the NIH CC) Suspected drug resistance (drug susceptible allowed at the NIH CC) Available to provide at least 3 sputa over 2 or more days Taking anti-tuberculosis medicines (or NTM meds at NIH CC) during the time sputa are provided Thought likely to be Mycobacterium culture positive (including NTM infected for the NIH CC) by enrolling physician GeneXpert MTB/RIF sputum TBpositive (China subjects only) Likely able to produce sputum samples while on study Willing to provide blood samples  Acute liver or kidney disease Conditions which compromise the subject s ability to take or absorb oral drugs
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  Cystic Fibrosis Patient Patient Without Treatment Against A.Fumigatus Patient with cystic fibrosis followed at Resource Centers and Cystic Fibrosis Skills (CRCM) Montpellier Patient aged 15 or over Patient able to understand the nature, purpose and methodology of the study Patient and his legal representative for minors who have given their free and informed consent Affiliate or beneficiary of a social security scheme  Patients on antifungal treatment at the time of sampling Pregnant or breastfeeding Major protected by law (guardianship, curator or under Backup Justice) Inability to understand the nature and goals of the study and / or communication difficulties with the investigator Subject attending another search including a period of still going to run-in
Patient description: An 18-year-old male returning from a recent vacation in Asia presents to the ER with a sudden onset of high fever, chills, facial flushing, epistaxis and severe headache and joint pain. His complete blood count reveals leukopenia, increased hematocrit concentration and thrombocytopenia.

Clinical trial eligibility criteria: eligible ages (years): 14.0-19.0,  Healthy Adolescents ages 14-19